Nature Reviews Drug Discovery volume 18, pages 585–608 (2019)Cite this article 82k Accesses 845 Citations 198 Altmetric Metrics details Abstract The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. BsAbs ...
In this Review, we discuss the role of bispecific antibodies in patients with cancer, including history and development, as well as innovative targeting strategies, clinical applications, and adverse events. We also discuss novel alternative bispecific antibody constructs, such as those targeting two ...
This review summarized the new development in blinatumomab (MT103/MEDI-538), a first-in-class bispecific T engager (BiTE) antibody against CD19/CD3 in patients with relapsed/refractory precursor B cell acute lymphoid leukemia.Targeted therapy has been the forefront of cancer treatment [1–7]. ...
Bi-specific T-cell engager,wikipedia treatment effect: 1( antibody for cancer cell)+1(antibody for T cell)>2 结合双抗原表位的双抗:不同于结合两个不同抗原的双抗,这种双抗则是选择结合同一个抗原不同的两个抗原表位,通过抗原交联和聚集增强结合强度,从而模仿抗体混合物和多克隆抗体的效果。目前国内百济...
双特异抗体(Bispecific antibody)是含有两个不同配体结合位点的免疫球蛋白分子。自然状态下不存在双特异性抗体,只能通过特殊方法进行制备。以往双特异抗体的制备方法有化学交联法,杂合F(ab')2 分子法和鼠杂交瘤法等。化学交联法生产双特异抗体的异源性,批与批之间的不稳定性,以及抗体特异性易受某些修饰或不当连接而...
Bispecific antibody-based therapeutics for the treatment of TNBC have gained recent attention in the scientific community. Clinical precedent has been previously established for the FDA-approved bispecific T cell engager, blinatumomab, for acute lymphoblastic leukemia. The present review discusses novel ...
Garfall, A.L. et al (2019). Trispecific antibodies off er a third way forward for anticancer immunotherapy. Nature, 575, 450-451. Ghose, S. et al (2005). Antibody variable region interactions with Protein A: Implications for the development of generic purification...
It discusses the disadvantages of the bispecific antibody blinatumomab submitted by biopharmaceutical company Amgen Inc. to the U.S. Food and Drug Administration (FDA) for regulatory review. It also presents a table that lists the bispecific antibodies in clinical development including Ertumaxomab from...
Nature Communications (2024) VH-CH1 switch region-inserting multispecific antibody designs and their efficacy against SARS-CoV-2 in vitro and in vivo Lili Wu Yue Gao Qihui Wang Cell Discovery (2023) Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses Yanjia Chen Xiaoyu...
These bispecific reagents demonstrate a superior safety profile compared to their parental CD40 monospecific antibody while triggering potent antitumor activity. We suggest such cell-selective bispecific agonistic antibodies as a drug platform to bypass the dose-limiting toxicities of anti-CD40, and of ...